

A British Thoracic Oncology Group phase III trial of Gemcitabine plus Cisplatin at 80 mg/m² versus Gemcitabine plus Cisplatin at 50 mg/m² versus Gemcitabine plus Carboplatin area under the concentration-time curve (AUC) 6 in stage IIIB/IV non-small cell lung cancer (NSCLC)

Submission date 05/08/2005	Recruitment status No longer recruiting	☐ Prospectively registered ☐ Protocol
Registration date 09/09/2005	Overall study status Completed	☐ Statistical analysis plan ☒ Results
Last Edited 12/10/2020	Condition category Cancer	☐ Individual participant data

Plain English summary of protocol

<https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-chemotherapy-for-advanced-non-small-cell-lung-cancer>

Contact information

Type(s)

Scientific

Contact name

Prof David Ferry

Contact details

Eli Lilly and Company
Bridgewater, NJ
United States of America

-

-

ferry_david@lilly.com

Additional identifiers

ClinicalTrials.gov (NCT)

NCT00112710

Protocol serial number

LU 3005

Study information

Scientific Title

A British Thoracic Oncology Group phase III trial of Gemcitabine plus Cisplatin at 80 mg/m² versus Gemcitabine plus Cisplatin at 50 mg/m² versus Gemcitabine plus Carboplatin area under the concentration-time curve (AUC) 6 in stage IIIB/IV non-small cell lung cancer (NSCLC)

Acronym

BTOG2

Study objectives

To establish the optimal cisplatin dose and whether carboplatin can be effectively substituted for the cisplatin at this dose

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration.

Primary study design

Interventional

Study design

Randomised controlled trial

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Non-small cell lung cancer

Interventions

Chemotherapy - Gemcitabine plus Cisplatin at 80 mg/m² versus Gemcitabine plus Cisplatin at 50 mg/m² versus Gemcitabine plus Carboplatin AUC 6

Intervention Type

Drug

Phase

Phase III

Drug/device/biological/vaccine name(s)

Gemcitabine, cisplatin, carboplatin

Primary outcome(s)

Length of survival

Key secondary outcome(s)

1. Symptom control and quality of life
2. Response to treatment
3. Dose intensity of chemotherapy
4. Ratio of cycles given as in-patient versus out-patient
5. Intensity, number and duration of toxic episodes (grade two to four)
6. Costs
7. Proteomic and genomic

Completion date

01/04/2008

Eligibility

Key inclusion criteria

1. Histologically or cytologically confirmed NSCLC (excluding mixed SCLC/NSCLC)
2. Radiologically verified stage IIIB (unsuitable for radical radiotherapy) or stage IV disease
3. Presence of one or more clinically or radiological measurable lesions by Response Evaluation Criteria in Solid Tumors (RECIST) criteria
4. World Health Organisation (WHO) Performance status zero, one or two
5. Aged over 18 years
6. Life expectancy more than 12 weeks
7. Adequate haematological function and hepatobiliary function
8. Creatinine clearance: 60 ml/min or 70 ml/min (51Cr-EDTA)
9. Able to participate in the quality of life assessment
10. Written informed consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Sex

All

Total final enrolment

1363

Key exclusion criteria

1. Prior chemotherapy or radiotherapy (prior surgical resection is allowed)
2. Evidence of severe or uncontrolled systemic diseases

3. Evidence of significant clinical disorder or laboratory finding
4. Concomitant or previous malignancy likely to interfere with protocol treatment or comparisons
5. Pre-existing neuropathy grade more than two
6. Clinically apparent metastatic disease to brain
7. Unresolved toxicity or incomplete recovery from previous surgery
8. Psychiatric disorder making informed consent impossible or preventing completion of treatment or follow-up
9. Previous investigational agent in the last 12 weeks
10. Male and female patients (of childbearing age) not using adequate contraception
11. Female patients who are pregnant or breast-feeding

Date of first enrolment

01/04/2005

Date of final enrolment

01/04/2008

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Royal Wolverhampton Hospitals NHS Trust

Wolverhampton

United Kingdom

WV10 0QP

Sponsor information

Organisation

University of Birmingham

ROR

<https://ror.org/03angcq70>

Funder(s)

Funder type

Charity

Funder Name

Cancer Research UK (CRUK)

Alternative Name(s)

CR_UK, Cancer Research UK - London, Cancer Research UK (CRUK), CRUK

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan**IPD sharing plan summary****Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/12/2011		Yes	No
Results article	results	01/09/2017	12/10/2020	Yes	No
Plain English results				No	Yes